The University of Southampton
University of Southampton Institutional Repository

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

Record type: Article

Background: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods.
Methods: The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
Results: In CP, hematologic remission was achieved in 97% and major (MCR) and complete cytogenetic remission (CCR) in 61% and 49% of patients, respectively. The chance to achieve MCR was higher in patients commencing imatinib earlier in the course of CML. In AP, the median survival period after the start of imatinib was 44 months, and MCR and CCR were observed in 31% and 26% of patients, respectively. In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively. Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.
Conclusions: The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy.

Full text not available from this repository.

Citation

Lahaye, Tanja, Riehm, Birte, Berger, Ute, Paschka, Peter, Müller, Martin C., Kreil, Sebastian, Merx, Kirsten, Schwindel, Uwe, Schoch, Claudia, Hehlmann, Rüdiger and Hochhaus, Andreas (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer, 103, (8), pp. 1659-1669. (doi:10.1002/cncr.20922).

More information

Published date: 2005
Keywords: chronic myeloid leukemia, imatinib, clinical strategies, hematologic resistance

Identifiers

Local EPrints ID: 24820
URI: http://eprints.soton.ac.uk/id/eprint/24820
ISSN: 0008-543X
PURE UUID: 5a073bf6-8a4c-4dfa-b46f-e2ccc69f62e8

Catalogue record

Date deposited: 03 Apr 2006
Last modified: 17 Jul 2017 16:12

Export record

Altmetrics

Contributors

Author: Tanja Lahaye
Author: Birte Riehm
Author: Ute Berger
Author: Peter Paschka
Author: Martin C. Müller
Author: Sebastian Kreil
Author: Kirsten Merx
Author: Uwe Schwindel
Author: Claudia Schoch
Author: Rüdiger Hehlmann
Author: Andreas Hochhaus

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×